Symrise AG (SWX:SY1)
Switzerland · Delayed Price · Currency is CHF | Market Cap | 9.49B -22.5% |
| Revenue (ttm) | 4.59B -1.4% |
| Net Income | 232.13M -47.9% |
| EPS | 1.66 -47.9% |
| Shares Out | n/a |
| PE Ratio | 40.87 |
| Forward PE | 18.73 |
| Dividend | 1.12 (1.69%) |
| Ex-Dividend Date | May 21, 2025 |
| Volume | n/a |
| Average Volume | 28 |
| Open | n/a |
| Previous Close | 66.36 |
| Day's Range | n/a |
| 52-Week Range | 65.84 - 69.80 |
| Beta | n/a |
| RSI | 20.14 |
| Earnings Date | Apr 29, 2026 |
About Symrise AG
Symrise AG operates as a supplier of fragrances, flavorings, cosmetic base materials and active ingredients, and functional ingredients and solutions in Europe, Africa, the Middle East, North America, the Asia Pacific, and Latin America. It operates in two segments, Taste, Nutrition & Health; and Scent & Care. The Taste, Nutrition & Health segment provides functional ingredients and product solutions used in the production of food and beverages; savory flavors; sweets, chocolate, chewing gum, baked goods, cereals, ice cream, milk, yogurt and mi... [Read more]
Financial Performance
In 2025, Symrise AG's revenue was 4.93 billion, a decrease of -1.39% compared to the previous year's 5.00 billion. Earnings were 249.33 million, a decrease of -47.86%.
Financial numbers in EUR Financial StatementsNews
Symrise and Aplantex Confirm an Agreement to Establish a Partnership
MONTREAL--(BUSINESS WIRE)--Symrise AG ("Symrise") and Aplantex Bio ("Aplantex") agree on a partnership covering new technologies for accessing plant-based molecules as raw material once the molecules ...
Hofseth Biocare ASA: HBC ACCELERATES IN HUMAN HEALTH AND PET NUTRITION THROUGH A STRATEGIC PARTNERSHIP WITH SYMRISE TO BUILD OUT BERKÅK, TRIPLING THE MANUFACTURING CAPACITY OF THE GROUP
HBC will accelerate its manufacturing scale and market reach with the construction of a second enzymatic hydrolysis plant in Berkåk, Norway. Symrise will support the financing of the project through a...